Evidence map›Paper›PMID 25168820›Full record

ArticleMolecular cancer2014

The chemokine receptor CXCR7 interacts with EGFR to promote breast cancer cell proliferation.

Nicole Salazar, Daniel Muñoz, Georgios Kallifatidis, Rajendra K Singh, Mercè Jordà, Bal L Lokeshwar

Open access · goldAbstract read
In one paragraph

Article in Molecular cancer, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed
4.0field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

44 citing papers in PubMed, 97 citations in OpenAlex.

  1. Review
  2. The role of CXC chemokines and receptors in breast cancer.Clinical and experimental medicine · 2025
    Review
  3. Article
  4. Article
  5. Crosstalk between purinergic receptor P2YCellular and molecular life sciences : CMLS · 2024
    Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Nicole Salazar
Daniel Muñoz
Georgios Kallifatidis
Rajendra K Singh
Mercè Jordà
Bal L LokeshwarSheila and David Fuente Graduate Program in Cancer Biology, University of Miami Miller School of Medicine, Miami, FL, USA. blokeshw@med.miami.edu.
University of Miami · USGeriatric Research Education and Clinical Center · US

Funding

University of Miami IMSD ProgramR25GM076419 · NIGMS · UNIVERSITY OF MIAMI CORAL GABLES · PI GAINES, MICHAEL S. · 2006 to 2016
$4.2M
Chemoprevention of Prostate Cancer by Allspice Derived Polyphenol: EricifolinR01CA156776 · NCI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI LOKESHWAR, BAL L · 2011 to 2016
$1.6M
Novel Mechanism of Breast Cancer Growth by CXCR7F31CA171787 · NCI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI SALAZAR, NICOLE · 2013 to 2014
$70k
Role of chemokine Receptor CXCR7 in prostate cancer progressionI01BX001517 · VA · MIAMI VA HEALTH CARE SYSTEM · PI LOKESHWAR, BAL L · 2012 to 2015
–
BLRD VA I01 BX001517NCI NIH HHS 1F31CA171787-01A1NCI NIH HHS F31 CA171787NCI NIH HHS R01 CA156776NCI NIH HHS R01CA156776NIGMS NIH HHS 1R25GM076419NIGMS NIH HHS R25 GM076419
6 · The paper itself

Abstract

backgroundRecent advances have revealed a significant contribution of chemokines and their receptors in tumor growth, survival after chemotherapy, and organ-specific metastasis. The CXC chemokine receptor-7 (CXCR7) is the latest chemokine receptor implicated in cancer. Although over expressed in breast cancer cell lines and tumor tissues, its mechanism of action in breast cancer (BrCa) growth and metastasis is unclear. Studies in other cancers have implicated CXCR7 in cell proliferation, anti-apoptotic activity and cell-cell adhesion. The present study was initiated to examine the pattern of CXCR7 expression and its role in regulation of growth signaling in breast cancer.

methodsThe contribution of CXCR7 in BrCa cell proliferation was investigated in representative cell lines using real time quantitative PCR (q-PCR), proliferation assays, immunohistochemistry and immunoblotting. Phenotypic changes were examined after CXCR7 specific cDNA and siRNA transfection and expression levels were monitored by q-PCR. Further, the association of CXCR7 with epidermal growth factor receptor (EGFR) and modulation of its activity were investigated by western blotting, immunofluorescence, and in-situ proximity ligation assays in human BrCa cells and tissues.

resultsCXCR7 was expressed in both, estrogen receptor (ER) positive and negative BrCa cell lines. CXCR7 was also expressed unevenly in normal breast tissues and to a much higher extent in ER + cancer tissues. Depletion of CXCR7 in MCF7 BrCa cells by RNA interference decreased proliferation and caused cell cycle arrest. Further, proximity ligation assay (PLA) revealed colocalization of CXCR7 with EGFR in cancer tissues and cancer cell lines. CXCR7 depletion reduced levels of phospho-EGFR at Tyrosine1110 after EGF-stimulation and also reduced phosphorylation of ERK1/2, indicating a potentially direct impact on mitogenic signaling in MCF7 cells. Using siRNA to knockdown β-arrestin2 in cells with EGFR over expression we were able to nearly deplete the CXCR7-EGFR colocalization events, suggesting that β-arrestin2 acts as a scaffold to enhance CXCR7 dependent activation of EGFR after EGF stimulation.

conclusionsThese results demonstrate coupling of CXCR7 with EGFR to regulate proliferation of BrCa cells and suggest an important ligand-independent role of CXCR7 in BrCa growth. Thus, the CXCR7-EGFR axis is a promising target for breast cancer therapy.

Indexed as

Arrestinsbeta-ArrestinsBreast NeoplasmsCell Line, TumorCell ProliferationErbB ReceptorsFemaleGene Knockdown TechniquesHumansMammary Glands, HumanMCF-7 CellsPhosphorylationReceptors, CXCRSignal TransductionACKR3 protein, humanArrestinsbeta-ArrestinsEGFR protein, humanErbB ReceptorsReceptors, CXCR

Identifiers

PMID25168820
PMCPMC4167278
OpenAlexW2156539818

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.